An overseas customer does not automatically make an Indian clinical-research service GST-free. The supply may be a zero-rated export only when every condition in section 2(6) of the Integrated Goods and Services Tax Act, 2017 (IGST Act) is satisfied, including a place of supply outside India. Section 13 can move the place of supply to India for specified goods-related work or services requiring an individual’s physical presence.
The result depends on the contract and the work actually performed: trial coordination, monitoring, laboratory testing, data analysis, participant-facing procedures and pass-through payments can raise different issues. Treat each deliverable and establishment relationship separately, document the analysis and verify current procedural requirements before filing returns or claiming a refund.
As an Amazon Associate I earn from qualifying purchases.
What must be true for an overseas clinical-research contract to be an export
Section 2(6) of the IGST Act sets five cumulative conditions for an export of services. “Cumulative” matters: failing one condition prevents export treatment, even if the customer is incorporated abroad and pays in foreign currency.
- Supplier located in India: the establishment that actually makes the supply must be in India.
- Recipient located outside India: identify the establishment that receives the service, not merely the group headquarters or the entity signing a master agreement.
- Place of supply outside India: determine this under section 13, including its special rules in subsections (3) to (13).
- Consideration received in permitted form: payment must be received in convertible foreign exchange or in Indian rupees wherever the Reserve Bank of India permits that form.
- No merely distinct establishments: supplier and recipient must not be establishments of the same person treated as distinct persons under the IGST Act.
| Condition | What to verify | Typical evidence |
|---|---|---|
| Supplier location | Which Indian GST-registered establishment performs and invoices the work? | Registration details, contract, statement of work and personnel records |
| Recipient location | Which legal entity or branch receives the deliverables and bears the contractual obligation? | Executed agreement, purchase order, tax registration and correspondence |
| Place of supply | Does section 13(2) apply, or does a special rule place the supply in India? | Service description, material-flow records and participant procedures |
| Payment | Was consideration received in convertible foreign exchange or an RBI-permitted rupee route? | Bank advice, remittance certificate or other permitted banking evidence |
| Distinct-person test | Are the parties separate legal persons rather than establishments of one person? | Corporate-structure documents and details of the contracting establishments |
All five conditions must be tested for each engagement. Foreign incorporation, a foreign bank account or a foreign-currency invoice is not a substitute for the place-of-supply and distinct-establishment tests.
#1 Best Overall
How section 13 determines the place of supply
Section 13 applies when the supplier or recipient is outside India. Its default rule in section 13(2) states: “The place of supply of services except the services specified in sub-sections (3) to (13) shall be the location of the recipient of services.” That usually points to the overseas recipient, but only after confirming that no special subsection governs the contracted service.
Services involving goods or materials made physically available
Section 13(3)(a) addresses services supplied in respect of goods that the recipient must physically make available to the supplier, or to a person acting for the supplier, so the service can be performed. In a clinical program, ask exactly what the foreign customer supplies: investigational medicines, reference products, biological samples, reagents, equipment or other items. Record whether the provider takes physical possession or control, why each item is needed, and what happens to it after testing or use.
The analysis is not triggered merely because a shipment crossed a border. If the contracted supply is principally trial coordination, site management, monitoring or statistical analysis, client-supplied materials may be incidental rather than the subject of the service. Conversely, a contract centered on testing or processing a supplied sample requires a closer section 13(3)(a) review. The statutory text also contains a temporary-import-and-re-export/process proviso whose conditions must be checked against the actual movement and return of goods.
Services requiring an individual’s physical presence
Section 13(3)(b) concerns services supplied to an individual that require that individual, or the individual’s representative, to be physically present with the supplier. Participant-facing clinical procedures should therefore be described precisely. Determine whether the service is supplied to the overseas sponsor or directly to an individual, whether the individual’s presence with the Indian provider is essential, and which entity is contractually receiving the result.
Why the statement of work matters
“Clinical research” is not one uniform GST category. A single master agreement may contain separate supplies with different factual profiles. Break out trial design, investigator and site coordination, monitoring visits, pharmacovigilance, laboratory testing, bioequivalence or bioavailability work, data management, statistical analysis, participant procedures and reimbursed third-party costs. Apply the place-of-supply analysis to each genuine supply rather than relying on a broad project label.
Clinical-research activities that need separate analysis
| Activity or charge | Questions that affect GST treatment | Evidence to retain |
|---|---|---|
| Trial design and protocol support | Is the work advisory or analytical, with no goods made available? | Deliverables, personnel roles and data-access terms |
| Site or investigator coordination | Where are coordination functions performed and which establishment receives them? | Work orders, site lists and reporting lines |
| Monitoring and quality oversight | Is the service performed for the foreign sponsor, and are visits merely performance activities rather than a separate participant service? | Monitoring plan, visit reports and acceptance records |
| Laboratory testing or sample analysis | Are samples or other goods physically made available, and are they the object of the service? | Sample logs, custody records, test methods and disposal or return records |
| Participant-facing procedures | Does section 13(3)(b) apply because an individual must be physically present? | Clinical procedure descriptions, consent workflow and contracting party |
| Pass-through payments | Is the provider supplying a service as principal, or acting as a disclosed pure agent for a local institution? | Agency clauses, invoices, authorization and exact reimbursement trail |
Do not assume that a pass-through amount follows the GST treatment of the main clinical service. The contractual role, markup, authorization and statutory pure-agent requirements must be examined independently.
A practical decision process for an Indian provider
- Map the parties. Write down the Indian supplier’s GSTIN and establishment, the legal entity named as recipient, the establishment that uses the output and any group-company branches involved.
- Confirm the relationship. Check whether the recipient is a separate legal person or merely another establishment of the same person. A foreign branch of the Indian entity may create a distinct-person problem even when the invoice is addressed overseas.
- Split the scope. Convert the statement of work into identifiable deliverables and charges. Avoid a single description such as “clinical research services” when the contract actually contains testing, monitoring, analysis and reimbursements.
- Trace materials. For every medicine, sample, reagent, device or reference product supplied by the customer, record shipment, custody, use, ownership and return or destruction.
- Check participant presence. Identify any service supplied to an individual and determine whether physical presence with the supplier is required.
- Apply section 13. Start with section 13(2), then test the special rules, including section 13(3)(a), section 13(3)(b) and any applicable proviso. State the conclusion for each deliverable and the facts supporting it.
- Verify payment compliance. Confirm the date and form of receipt, foreign-exchange conversion and any RBI-permitted rupee arrangement. Keep banking evidence matched to invoices.
- Select the zero-rated procedure only after the tests pass. Recheck current return, invoicing, LUT, bond and refund rules for the relevant tax period.
What zero-rated treatment means
Export of services is zero-rated, which is different from an exempt supply. Zero-rating preserves statutory input-tax-credit and refund mechanisms, subject to the conditions and procedures in force. CBIC’s sectoral FAQ describes two broad routes:
Quick wins for a faster PC:
Fix the driver behind crashes, sound loss and screen glitchesFind Drivers →Repair Windows errors before they cause bigger problemsFix Now →- LUT or bond route: supply without payment of IGST under a valid letter of undertaking or bond and claim a refund of eligible unutilized input tax credit, following the applicable filing and documentary requirements.
- Tax-payment route: pay IGST on the export invoice and claim a refund of that IGST when the statutory conditions and refund procedure are met.
These are not automatic elections that cure an incorrect place-of-supply conclusion. Maintain the agreement, invoice, export documentation, remittance proof, LUT or bond records, return data, input-tax-credit ledger and refund calculation. Check amendments, notifications and portal requirements for the period in which the supply is reported.
What official clinical-research records do—and do not—establish
Older advance-ruling records are useful for issue spotting but must be read within their facts. They are not a universal classification for every contract or every clinical-research provider.
| Record | What is publicly identified | How to use it safely |
|---|---|---|
| Cliantha Research Limited, Maharashtra | Order GST-ARA-119/2018-19/B-50, Mumbai, dated 4 May 2019; the listed issue concerns proposed clinical-research services to entities outside India. | Review the complete order, including its operative conclusion and factual assumptions, before relying on it. |
| Asiatic Clinical Research Private Limited, Karnataka | Order KAR/AAR/80/2019-20 dated 24 September 2019; issues include export status and amounts paid onward to local research institutions as a possible pure-agent question. | The issue listing alone does not disclose the reasoning or answer. Do not infer a result from the title. |
| Parexel International Clinical Research, Karnataka | An order concerning clinical-trial coordination and monitoring in India and discussion of section 13(3). | Read the full order and compare its contract and activities with the proposed engagement before drawing any analogy. |
| GST Council 37th-meeting agenda material | Historical discussion of pharmaceutical R&D, processing and testing, bioequivalence and bioavailability studies, and clinical trials involving client-supplied materials. | Agenda analysis is explanatory context, not enacted law or a binding ruling. |
The statutory text, current notifications and the complete operative portions of any ruling take priority over summaries or issue descriptions.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.Worked fact patterns
Coordination and data analysis with no client materials
An Indian provider coordinates investigators, monitors sites and analyzes trial data for a separately incorporated overseas sponsor. No goods are made available for the provider’s work, and the sponsor receives the deliverables. If payment and distinct-person conditions are also satisfied, section 13(2) may place the supply at the sponsor’s location, supporting export treatment. The conclusion still depends on the actual contract and recipient establishment.
Recommended Free Tools
Testing a sponsor-supplied sample
The sponsor ships a reference sample to India, and the Indian laboratory’s contracted deliverable is testing that sample. Because the service is directly concerned with goods made physically available, section 13(3)(a) requires specific analysis. Document custody, testing purpose and return or disposal; do not apply the recipient-location default without addressing this subsection and its proviso.
Participant procedure performed in India
A contract requires an Indian provider to perform a procedure on an individual who must be physically present. Determine whether the service is supplied to that individual or to the overseas sponsor and whether section 13(3)(b) applies. The invoice label alone cannot resolve the question.
Common errors and corrective controls
- Error: treating “foreign client” as the whole test. Control: complete a signed five-condition section 2(6) checklist for every supply.
- Error: ignoring branches and group establishments. Control: identify the receiving establishment and map the legal-person relationship in the contract.
- Error: bundling laboratory work with coordination. Control: separate deliverables, prices, material flows and place-of-supply conclusions.
- Error: assuming foreign-currency receipt proves export. Control: retain permitted remittance evidence and verify the place of supply independently.
- Error: relying on an old AAR headline. Control: read the operative order, date, jurisdiction and facts; check later law and notifications.
- Error: calling zero-rated supplies exempt. Control: use the correct LUT, bond, tax-payment and refund procedure for the period.
- Error: omitting participant and sample details. Control: attach a service-flow annex to the agreement describing who is present, what is supplied and where each activity occurs.
Contract and audit file checklist
- Executed master services agreement and each statement of work.
- Legal names, addresses, GST registrations and establishment details for supplier and recipient.
- Deliverable matrix separating coordination, monitoring, testing, analysis, participant procedures and reimbursements.
- Material-flow schedule covering medicines, samples, reagents, devices and return or destruction.
- Participant-facing procedure descriptions and evidence of where physical presence is required.
- Invoices that identify the recipient, service period, consideration and chosen tax treatment.
- Foreign-exchange or permitted-rupee receipt evidence linked to each invoice.
- LUT or bond, export documentation, returns, input-tax-credit records and refund workings where applicable.
- Written place-of-supply memo citing the relevant section 13 rule for each distinct supply.
Bottom line
Clinical research supplied from India to an overseas client may be a zero-rated export, but only when all section 2(6) conditions are met and the applicable section 13 rule places the supply outside India. A foreign customer and foreign-currency payment are not enough. The decisive work is factual: identify the true recipient and establishment, describe each service, trace any goods made available, test participant-presence rules, verify payment and distinct-person status, then follow the current LUT, return and refund procedures.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
Free tools Windows power users keep installed
One-click scans. No signup required.
